CD38 and systemic sclerosis: Although we found an increase of CD38+ regulatory B and T cells in this SSc cohort, suggesting a potential limitation of the use of anti-CD38 therapy in patients with SSc, it is thought that these populations are functionally impaired in SSc, thus their role is highly controversial (36–40).